<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103359</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0701</org_study_id>
    <secondary_id>2019-A01877-50</secondary_id>
    <nct_id>NCT04103359</nct_id>
  </id_info>
  <brief_title>Comparison of Lower-risk MDS Patients With and Without Improvements in Fatigue Following Blood Transfusion Therapy</brief_title>
  <acronym>FITME</acronym>
  <official_title>Fatigue in Myelodysplasic Patients : Why Blood Transfusion Does Not Systematically Improve Symptoms? (FITME Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoire Interuniversitaire de Biologie de la Motricité - Jean Monnet University Saint-Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, it is unclear why some myelodysplastic patients (MDS) receiving blood transfusion
      therapy exhibit an increase in Hemoglobin (Hb) without a concurrent improvement in fatigue.
      Research is thus required to elucidate on why fatigue persists in some MDS patients in order
      to devise strategies to alleviate fatigue in &quot;non-responders&quot; to blood transfusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hypothesis is that patients who exhibited persistent fatigue following a blood-
      transfusion- induced increase in Hb have an impaired ability to utilize oxygen at the
      peripheral level. This could be the consequence of impairments in vascular function, mediated
      by endothelial dysfunction as a result of transfusion-induced iron-overload and oxidative
      stress associated with the disease. Taking the current gaps in knowledge pertaining to
      MDS-related fatigue into account, the objective of this study is to improve understanding on
      the aetiology fatigue in MDS patients. To achieve this aim, the study will measure a
      comprehensive group of patient-reported and disease-related outcomes: i) prior to blood
      transfusion therapy when Hb levels are low and; ii) following blood transfusion therapy, when
      Hb levels have been increased. Results from the post-transfusion tests will be analyzed to
      determine which participants remain fatigued despite an increase in Hb, and which
      participants shown an improvement in fatigue.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Fatigue using FACIT-F questionnaire</measure>
    <time_frame>10 days</time_frame>
    <description>Measurement of Fatigue will be performed using FACIT-F questionnaire. This is a questionnaire with 13 questions about which the patient is positioned on a Likert scale ranging from 1 to 5 (1 = quite, 5 = not at all). By adding the answers, a score out of 65 is obtained. Unlike other scales the higher the score the less the patient is tired. As an indication, the non-sick average positions is 40.1 on this scale.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Myelodysplatic Syndromes</condition>
  <arm_group>
    <arm_group_label>MDS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MDS patients receiving blood transfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physiological tests to measure fatigue level</intervention_name>
    <description>Physiological tests to measure fatigue level</description>
    <arm_group_label>MDS patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient affiliated to a social security regimen or beneficiary of the same

          -  Signed written informed consent form

          -  Patient, ≥ 18 years-old, with established diagnosis of myelodysplastic syndrome with
             low or intermediate-1 risk cytogenetic profile

          -  FACIT-F score ≤ 34,

          -  Indication of blood transfusion.

        Exclusion Criteria:

          -  Contra-indication to experimental procedures and/or physical exercise,

          -  Concomitant cancer diagnosis,

          -  Patient under guardianship or deprived of his liberty or any condition that may affect
             the patient's ability to understand and sign the informed consent

          -  Refusing participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Guyotat, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie Lucien Neuwirth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denis Guyotat, PhD, MD</last_name>
    <phone>0477917000</phone>
    <phone_ext>+33</phone_ext>
    <email>denis.guyotat@icloire.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Daguenet, PhD</last_name>
    <phone>0477917089</phone>
    <phone_ext>+33</phone_ext>
    <email>elisabeth.daguenet@icloire.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Denis Guyotat, PhD, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Elisabeth Daguenet, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Denis Guyotat, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle Portois, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie Chalayer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karine Augeul-Meunier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplatic syndromes</keyword>
  <keyword>elderly</keyword>
  <keyword>fatigue</keyword>
  <keyword>blood transfusion</keyword>
  <keyword>physiopathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

